STOCK TITAN

Neuropace Inc - NPCE STOCK NEWS

Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.

NeuroPace Inc (NPCE) is a pioneering medical technology company developing brain-responsive neuromodulation systems for epilepsy treatment. This page serves as the definitive source for official company announcements, financial updates, and clinical progress reports.

Access timely updates on NPCE's innovative RNS System, including FDA regulatory milestones, partnership developments with leading epilepsy centers, and peer-reviewed clinical study results. Investors will find earnings reports and strategic initiatives, while healthcare professionals can track real-world treatment outcomes and technological refinements.

Our curated news collection features:
- Quarterly financial performance updates
- RNS System enhancement announcements
- Clinical trial data publications
- Regulatory clearance milestones
- Research collaborations with medical institutions

Bookmark this page for structured access to NPCE's evolving role in neurotechnology and epilepsy care innovation.

Rhea-AI Summary
NeuroPace, Inc. (NPCE) to present at Piper Sandler 35th Annual Healthcare Conference, with CEO Joel Becker providing a corporate presentation on November 28 at 2:30pm ET. The company will also participate in one-on-one meetings with investors during the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
conferences
-
Rhea-AI Summary
NeuroPace, Inc. reports Q3 2023 revenue of $16.4 million, a 47% YoY increase. Full-year revenue guidance raised to $62.5-$63.5 million. Cash burn reduced to $2.2 million in Q3 2023. Gross margin improves to 74.5%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
-
Rhea-AI Summary
NeuroPace announces enhancements to its RNS System to streamline care for epilepsy patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
none
Rhea-AI Summary
NeuroPace, Inc. will report Q3 2023 financial results on November 6, 2023, after market close. A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET. Webcast and telephone access available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
conferences earnings
-
Rhea-AI Summary
NeuroPace to participate in fireside chat at Cantor Fitzgerald Global Healthcare Conference on September 28, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
conferences
-
Rhea-AI Summary
NeuroPace, Inc. to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.28%
Tags
conferences
Rhea-AI Summary
NeuroPace reports Q2 2023 revenue of $16.5M, up 62% YoY. Full-year revenue guidance increased to $59-$61M. Cash burn reduced to $4M in Q2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.76%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.05%
Tags
conferences earnings
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.21%
Tags
none
Neuropace Inc

Nasdaq:NPCE

NPCE Rankings

NPCE Stock Data

351.32M
23.73M
3.38%
61.73%
0.75%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MOUNTAIN VIEW